Cargando…

Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy

BACKGROUND: Invasive lobular carcinoma (ILC) of the breast is known for high risk of late recurrence, yet some patients still recur within 5 years of diagnosis. Determining factors associated with early/late recurrence could help tailor treatment and surveillance strategies. METHODS: Using an instit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothschild, Harriet T., Clelland, Elle N., Mujir, Firdows, Record, Helena, Wong, Jasmine, Esserman, Laura J., Alvarado, Michael, Ewing, Cheryl, Mukhtar, Rita A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495501/
https://www.ncbi.nlm.nih.gov/pubmed/37464134
http://dx.doi.org/10.1245/s10434-023-13881-x
_version_ 1785104910459600896
author Rothschild, Harriet T.
Clelland, Elle N.
Mujir, Firdows
Record, Helena
Wong, Jasmine
Esserman, Laura J.
Alvarado, Michael
Ewing, Cheryl
Mukhtar, Rita A.
author_facet Rothschild, Harriet T.
Clelland, Elle N.
Mujir, Firdows
Record, Helena
Wong, Jasmine
Esserman, Laura J.
Alvarado, Michael
Ewing, Cheryl
Mukhtar, Rita A.
author_sort Rothschild, Harriet T.
collection PubMed
description BACKGROUND: Invasive lobular carcinoma (ILC) of the breast is known for high risk of late recurrence, yet some patients still recur within 5 years of diagnosis. Determining factors associated with early/late recurrence could help tailor treatment and surveillance strategies. METHODS: Using an institutional database, we evaluated patients with ILC and ≥ 5 years of follow-up or recurrence within 5 years. We used multivariate logistic regression and the Kaplan-Meier method to evaluate which clinicopathologic features and treatment strategies were associated with recurrence < 5 years since diagnosis versus recurrence ≥ 5 years since diagnosis. Additionally, we explored the association between Clinical Treatment Score 5 (CTS5) with early versus late recurrence. RESULTS: Among 513 cases of stage I–III ILC, there were 75 early and 54 late recurrences during a median follow-up period of 9.4 years. Early recurrence was associated with larger tumors (mean 4.2 cm vs. 2.9 cm, p < 0.0001), higher incidence of > 3 positive nodes (32.4% vs. 9.11%, p > 0.0001), and more aggressive tumor biology (low/negative progesterone receptor expression, higher grade, and higher Ki67). Late recurrence was associated with younger age (mean 55.6 vs. 59.2 years, p = 0.037) and elevated body mass index (BMI > 25 kg/m(2) in 60.1.0% vs. 45.4%, p = 0.021). Omission of adjuvant endocrine therapy or radiotherapy after lumpectomy conferred increased risk of early rather than late recurrence. CONCLUSION: Factors related to tumor aggressiveness and treatment were associated with early recurrence, whereas patient related factors were related to late recurrence. These data may help guide treatment strategies and surveillance approaches for patients with ILC.
format Online
Article
Text
id pubmed-10495501
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104955012023-09-13 Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy Rothschild, Harriet T. Clelland, Elle N. Mujir, Firdows Record, Helena Wong, Jasmine Esserman, Laura J. Alvarado, Michael Ewing, Cheryl Mukhtar, Rita A. Ann Surg Oncol Breast Oncology BACKGROUND: Invasive lobular carcinoma (ILC) of the breast is known for high risk of late recurrence, yet some patients still recur within 5 years of diagnosis. Determining factors associated with early/late recurrence could help tailor treatment and surveillance strategies. METHODS: Using an institutional database, we evaluated patients with ILC and ≥ 5 years of follow-up or recurrence within 5 years. We used multivariate logistic regression and the Kaplan-Meier method to evaluate which clinicopathologic features and treatment strategies were associated with recurrence < 5 years since diagnosis versus recurrence ≥ 5 years since diagnosis. Additionally, we explored the association between Clinical Treatment Score 5 (CTS5) with early versus late recurrence. RESULTS: Among 513 cases of stage I–III ILC, there were 75 early and 54 late recurrences during a median follow-up period of 9.4 years. Early recurrence was associated with larger tumors (mean 4.2 cm vs. 2.9 cm, p < 0.0001), higher incidence of > 3 positive nodes (32.4% vs. 9.11%, p > 0.0001), and more aggressive tumor biology (low/negative progesterone receptor expression, higher grade, and higher Ki67). Late recurrence was associated with younger age (mean 55.6 vs. 59.2 years, p = 0.037) and elevated body mass index (BMI > 25 kg/m(2) in 60.1.0% vs. 45.4%, p = 0.021). Omission of adjuvant endocrine therapy or radiotherapy after lumpectomy conferred increased risk of early rather than late recurrence. CONCLUSION: Factors related to tumor aggressiveness and treatment were associated with early recurrence, whereas patient related factors were related to late recurrence. These data may help guide treatment strategies and surveillance approaches for patients with ILC. Springer International Publishing 2023-07-18 2023 /pmc/articles/PMC10495501/ /pubmed/37464134 http://dx.doi.org/10.1245/s10434-023-13881-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Breast Oncology
Rothschild, Harriet T.
Clelland, Elle N.
Mujir, Firdows
Record, Helena
Wong, Jasmine
Esserman, Laura J.
Alvarado, Michael
Ewing, Cheryl
Mukhtar, Rita A.
Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
title Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
title_full Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
title_fullStr Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
title_full_unstemmed Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
title_short Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
title_sort predictors of early versus late recurrence in invasive lobular carcinoma of the breast: impact of local and systemic therapy
topic Breast Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495501/
https://www.ncbi.nlm.nih.gov/pubmed/37464134
http://dx.doi.org/10.1245/s10434-023-13881-x
work_keys_str_mv AT rothschildharriett predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT clellandellen predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT mujirfirdows predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT recordhelena predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT wongjasmine predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT essermanlauraj predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT alvaradomichael predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT ewingcheryl predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy
AT mukhtarritaa predictorsofearlyversuslaterecurrenceininvasivelobularcarcinomaofthebreastimpactoflocalandsystemictherapy